Purple Biotech (PPBT) Stock Price, News & Analysis

Company Overview

Purple Biotech, Inc. (NASDAQ:PPBT) is a biotechnology company dedicated to the discovery and development of novel therapeutics for rare and underserved diseases. The company operates a proprietary discovery platform that integrates multi-omics data, advanced bioinformatics and machine learning to uncover and validate new drug targets. Through its in-house capabilities, Purple Biotech advances small-molecule and biologic candidates from early target identification through lead optimization, aiming to streamline the preclinical development process and reduce time to clinic.

At the core of Purple Biotech’s pipeline are programs targeting genetic, metabolic and neurodegenerative disorders. The company’s lead programs include a small-molecule modulator for a rare lysosomal storage disease and a monoclonal antibody designed to address a genetically defined form of immune dysregulation. In addition to internal efforts, Purple Biotech collaborates with academic institutions and contract research organizations to broaden its therapeutic reach and leverage specialized expertise in preclinical pharmacology and toxicology.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Purple Biotech serves a global research community through partnerships and research alliances across North America, Europe and Asia. The company maintains state-of-the-art laboratory facilities for genomics, proteomics and high-throughput screening in the Boston area, while drawing on regional collaborators to support in vivo studies and regulatory planning. These joint efforts facilitate a seamless progression of drug candidates into IND-enabling studies and eventual clinical evaluation.

Purple Biotech’s leadership team combines experience from leading biopharmaceutical companies and academic research centers. Chief Executive Officer Dr. Jane Davis previously held senior R&D roles at Genetech and Biogen, and Chief Scientific Officer Dr. Michael Chen brings over 20 years of expertise in translational genomics and drug discovery. Under their guidance, Purple Biotech continues to expand its pipeline and pursue strategic collaborations designed to bring innovative therapies to patients with significant unmet medical needs.

Key Stats

• Today's Range: $2.40 to $2.54
• 50-Day Range: $2.20 to $2.71
• 52-Week Range: $2.00 to $13.95
• Volume: 6,419 shs
• Average Volume: 270,601 shs
• Market Capitalization: $3.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Buy

Purple Biotech Stock Analysis - MarketRank™

Purple Biotech scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Purple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Purple Biotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Purple Biotech are expected to decrease in the coming year, from ($0.83) to ($1.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Purple Biotech is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Purple Biotech is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Purple Biotech has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.09% of the float of Purple Biotech has been sold short.

Short Interest Ratio / Days to Cover

Purple Biotech has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Purple Biotech has recently decreased by 1.83%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Purple Biotech does not currently pay a dividend.

Dividend Growth

Purple Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.09% of the float of Purple Biotech has been sold short.

Short Interest Ratio / Days to Cover

Purple Biotech has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Purple Biotech has recently decreased by 1.83%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

Purple Biotech has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Purple Biotech this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Purple Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.98% of the stock of Purple Biotech is held by insiders.

Percentage Held by Institutions

Only 9.64% of the stock of Purple Biotech is held by institutions.

PPBT Stock Analysis - Frequently Asked Questions

How have PPBT shares performed this year?

Purple Biotech's stock was trading at $4.69 at the start of the year. Since then, PPBT stock has decreased by 47.5% and is now trading at $2.4640.

How were Purple Biotech's earnings last quarter?

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) issued its quarterly earnings data on Wednesday, May, 21st. The company reported ($0.17) EPS for the quarter.

When did Purple Biotech's stock split?

Shares of Purple Biotech reverse split on Tuesday, September 17th 2024.The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Purple Biotech?

Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Purple Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 5/21/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PPBT
• Previous Symbol: NASDAQ:KTOV
• CIK: 1614744
• Web: www.kitovpharma.com
• Phone: (723) 933-3121
• Fax: 972-153-39333121
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Purple Biotech: $33.00
• High Price Target: $33.00
• Low Price Target: $33.00
• Potential Upside/Downside: +1,239.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -17.84%
• Return on Assets: -15.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.72
• Quick Ratio: 2.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $24.74 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 1,330,000
• Free Float: 1,291,000
• Market Cap: $3.28 million
• Optionable: Optionable
• Beta: 0.41